Michael A. Caligiuri, MD
MICHAEL A . CALIGIURI, MD, President of City of Hope National Medical Center, and Deana and Steve Campbell Physician-in-Chief Distinguished Chair, has been elected to the National Academy of Medicine, one of the highest honors in the fields of health and medicine. Membership in the Academy recognizes individuals who have demonstrated outstanding professional achievements and commitment to service.
“City of Hope is pleased that Dr. Caligiuri has been elected to the National Academy of Medicine, a highly distinguished group of medical, health, and public health leaders,” said City of Hope President and Chief Executive Officer Robert W. Stone. “This honor is a testament to his dedication to patients and his contributions to cancer research and science.”
Robert W. Stone
New members are elected by current members through a process that recognizes individuals who have made major contributions to the advancement of the medical sciences, health care, and public health.
Current Goals and Roles
KNOWN FOR his immunology research on human natural killer cells, Dr. Caligiuri is a physician, scientist, builder, innovator, leader, and visionary who is dedicated to developing the next generation of leading-edge cancer therapies, rapidly delivering them to patients, and ultimately curing the disease.
Dr. Caligiuri joined City of Hope in February 2018. His goals there are “to speed up the delivery of our discoveries in the laboratory to our patients,” to use his inclusive leadership style to foster greater collaboration across the institution and with other institutions, and to “optimize the patient care system to ensure the highest quality and safest patient experience.”
PRIOR TO JOINING City of Hope, Dr. Caligiuri worked as a physician, scientist, and leader in the cancer program at The Ohio State University. He spent the past decade as Chief Executive Officer of The James Cancer Hospital and Solove Research Institute and directed The Ohio State University Comprehensive Cancer Center for 14 years, recruiting over 300 cancer physicians and scientists.
Dr. Caligiuri is also the Immediate Past President of the American Association for Cancer Research. In addition, he was also recently named a fellow of that organization.
As a physician-scientist, Dr. Caligiuri’s research focuses on the development and activation of human natural killer cells and their modulation for the treatment of leukemia, myeloma, and glioblastoma. More than 1,000 patients with cancer have been treated on clinical protocols that have emanated from Dr. Caligiuri’s laboratory. He also has trained more than 120 undergraduate, graduate, or postgraduate students in his laboratory. ■